Prestige Consumer Healthcare (PBH) Issues FY19 Earnings Guidance

Share on StockTwits

Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY19 earnings guidance on Monday morning. The company provided EPS guidance of $2.75-2.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.88. The company issued revenue guidance of $970-975 million, compared to the consensus revenue estimate of $989.03 million.

Shares of NYSE:PBH opened at $31.38 on Monday. Prestige Consumer Healthcare has a twelve month low of $27.84 and a twelve month high of $46.44. The company has a market cap of $1.60 billion, a PE ratio of 12.16, a PEG ratio of 1.53 and a beta of 1.19. The company has a current ratio of 2.15, a quick ratio of 1.38 and a debt-to-equity ratio of 1.59.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.02. Prestige Consumer Healthcare had a return on equity of 11.82% and a net margin of 33.38%. The company had revenue of $239.36 million during the quarter, compared to the consensus estimate of $236.28 million. During the same quarter in the prior year, the company earned $0.61 EPS. The firm’s quarterly revenue was down 7.2% compared to the same quarter last year. Equities analysts predict that Prestige Consumer Healthcare will post 2.88 EPS for the current fiscal year.

Several equities analysts have recently commented on PBH shares. Zacks Investment Research upgraded Prestige Consumer Healthcare from a hold rating to a buy rating and set a $35.00 price objective on the stock in a research report on Wednesday, January 2nd. ValuEngine upgraded Prestige Consumer Healthcare from a sell rating to a hold rating in a research report on Wednesday, November 7th. Finally, DA Davidson increased their price objective on Prestige Consumer Healthcare to $38.00 and gave the company a neutral rating in a research report on Monday, November 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $38.50.

In other Prestige Consumer Healthcare news, EVP Timothy Connors sold 34,000 shares of the business’s stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $38.25, for a total transaction of $1,300,500.00. Following the completion of the sale, the executive vice president now owns 25,775 shares of the company’s stock, valued at $985,893.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.14% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by BBNS and is owned by of BBNS. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://baseballnewssource.com/2019/01/14/prestige-consumer-healthcare-pbh-issues-fy19-earnings-guidance/3140107.html.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American Over-the-Counter (OTC) Healthcare, International OTC Healthcare, and Household Cleaning. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.

Featured Article: Differences Between Momentum Investing and Long Term Investing

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.